// App-Quantinova.ai

6568 : Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).

Researchers

Presenter

  • Robert J. Motzer

Principal Investigators

  • Toni K. Choueiri

  • Jessica May

  • Youngmin Kwon

  • Nifasha Rusibamayila

  • Marc Botteman

  • Melissa Hamilton

  • Flavia Ejzykowicz

  • David Cella

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA

  • Bristol Myers Squibb, Middlesex, United Kingdom

  • Pharmerit, An OPEN Health Company, Bethesda, MD

  • Pharmerit, An OPEN Health Company, Bethesda, MD

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02231749

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved